1. Cyclovirobuxine D(CVB-D) has been widely used for treatment of cardiac insufficiency and arrhythmias in China, the antiarrhythmic and proarrhythmic potential of this drug might be concerned with prolongation of action potential duration and QT interval.
2. Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction and supports the potential for cyclovirobuxine D as a new therapy for heart failure.
3. Cyclovirobuxine D can induce autophagy in the MCF-7 human breast cancer cell line, CVB-D-induced autophagy and decrease in cell viability could be blocked by 3-methyladenine, a well-established autophagy inhibitor, moreover.
4. Cyclovirobuxine D can attenuate the phosphorylation of Akt and mTOR, two pivotal suppressors in autophagy pathways;these findings may support the potential utility of autophagy inducers in cancer treatment.
5. Cyclovirobuxine D shows vasorelaxant effect.
1. Neferine has anti-tumor activities , Metabolic activation mediated by CYP3A4 and GSH depletion enhanced Neferine-induced cytotoxicity.
2. Neferine can be helpful to increase the efficacy of DOX and to achieve anticancer synergism by curbing the toxicity.
3. Neferine inhibited high glucose-induced endothelial apoptosis via blocking ROS/Akt/NF-κB pathway, which provides the evidence for using Neferine to treat diabetic vasculopathy.
4. Neferine induced apoptosis in a dose-dependent manner with the hypergeneration of reactive oxygen species, activation of MAPKs, lipid peroxidation, depletion of cellular antioxidant pool, loss of mitochondrial membrane potential, and intracellular calcium accumulation.
1. Saikosaponin is a novel SERCA inhibitor by inhibiting NF-κB and STAT3 signaling to protect against acetaminophen-induced hepatotoxicity.
2. Saikosaponin is a potent inhibitory on acute hepatic injury by CCl4 and a potent cytotoxicity agent for human hepatocellular carcinoma cells.
3. Saikosaponin has the antiproliferative effect in A549 cells that may be the induction of p53 and activity of the Fas/FasL apoptotic system.
1. Fisetin is an anti-inflammatory flavonoid.
2. Fisetin has antimetastatic effects on prostate, breast and lung cancers.
3. Fisetin has beneficial effect on periodontal disease, may via inhibiting MAPK activation and COX-2 expression without affecting cell viability.
4. Fisetin suppresses the accumulation of intracellular lipids by inhibiting GLUT4-mediated glucose uptake through inhibition of the mTOR-C/EBPα signaling in 3T3-L1 cells.
5. Fisetin can inhibit UV-induced intracellular reactive oxygen species (ROS), prostaglandin E2 (PGE2), and nitric oxide (NO) generation, may be used in the development of photoprotective agents.
1. Madurensine and doronenine show moderate cytotoxicity on cancerous U-937 cells (IC(50) values: 47.97 and 29.57 M respectively).
2. Madurensine induces autophagy, which in prolonged circumstances may lead to autophagic cell death.